20 results on '"Moulton, Brian"'
Search Results
2. Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
3. Abstract 5584: Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients
4. Abstract P1-11-09: Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer
5. Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
6. Save European research campaign
7. Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)
8. Two years later: the impact of the EU directive: why research in Europe has declined since the implementation of the Clinical Trials Directive
9. Mature results of a phase I/II evaluation of docetaxel (T), ifosphamide (I), cisplatin (C) supported by lenograstim (L) in patients (pts) with advanced non-small cell lung cancer (NSCLCa): An Irish Clinical Oncology Research Group (ICORG) study.
10. Coordination polymers: toward functional transition metal sustained materials and supermolecules
11. A Neutral “Molecular Railroad” Coordination Polymer That Incorporates Polycyclic Aromatic Molecules: Synthesis and Single-Crystal X-Ray Structure of [Co(4,4′bipyridine)2.5(NO3)2]·2Phenanthrene
12. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
13. Additional file 2: Table S2. of Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
14. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
15. Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer
16. Phase II clinical trial of first or second-line treatment with Bortezomib in patients with malignant pleural mesothelioma
17. Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),
18. Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.
19. Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.
20. Save European research campaign.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.